AmitaPatnaikMD

Oncology • San Antonio, TX

Physician

Join to view full profile

Dr. Patnaik is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Patnaik's full profile

Already have an account?

Office
4383 Medical Dr
San Antonio, TX 78229
Phone+1 210-593-5700

Fax+1 210-593-5992

Education & Training

University of Toronto Faculty of MedicineClass of 1992

Certifications & Licensure

TX State Medical License 2000 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors:SE Texas Castle Connolly, 2013

Clinical Trials

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02) Start of enrollment: 2007 May 01
Completed
Phase 1
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Jan 01
Completed
Phase 1
A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors Start of enrollment: 2013 Feb 01
Completed
Phase 1
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
No longer available
Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. Start of enrollment: 2014 Jun 27
Completed
Phase 1
Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors Start of enrollment: 2015 Jun 01
Active, not recruiting
Phase 1
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Start of enrollment: 2015 Sep 01
Completed
Phase 1
A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors Start of enrollment: 2017 Apr 12
Completed
Phase 1
Study of SRF617 in Patients With Advanced Solid Tumors Start of enrollment: 2020 Mar 16
Completed
Phase 1
A Study of SGN-B6A in Advanced Solid Tumors Start of enrollment: 2020 Jun 08
Recruiting
Phase 1
A Study of SGN-STNV in Advanced Solid Tumors Start of enrollment: 2021 Jan 18
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
A First-in-Human Study of cinrebafusp alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.
Sarina Piha-Paul, Shane A Olwill, Erika Hamilton, Anthony Tolcher, Paula Pohlmann
Clinical Cancer Research. 2024-09-05
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab ...
Diwakar Davar, Ludimila Cavalcante, Nehal Lakhani, Justin Moser, Michael Millward
Journal for Immunotherapy of Cancer. 2024-08-03
Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells.
Dana Piovesan, Amber E de Groot, Soonweng Cho, Amy E Anderson, Rebecca D Ray
Cancer Research. 2024-06-14

Lectures

Phase ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

selfBACK App Developed by Norwegian University of Science Can Help Relieve Back PainAugust 3rd, 2021
START Launches New Phase I Clinical Trial Program in UtahJune 8th, 2021
Nektar Therapeutics Announces Its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC)May 18th, 2021
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member